Delayed
Japan Exchange
07:00:00 15/05/2024 BST
|
5-day change
|
1st Jan Change
|
1,665
JPY
|
-4.31%
|
|
-5.51%
|
-11.95%
|
Fiscal Period: March |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
23,841
|
17,331
|
12,352
|
-
|
-
|
Enterprise Value (EV)
1 |
23,452
|
17,014
|
14,162
|
12,478
|
12,025
|
P/E ratio
|
71.7
x
|
45
x
|
32.1
x
|
16.6
x
|
12.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
4.12
x
|
2.6
x
|
1.71
x
|
1.24
x
|
1.06
x
|
EV / Revenue
|
4.06
x
|
2.56
x
|
1.71
x
|
1.25
x
|
1.03
x
|
EV / EBITDA
|
39.2
x
|
27.4
x
|
14.9
x
|
10.6
x
|
7.8
x
|
EV / FCF
|
73.5
x
|
-
|
59.5
x
|
48
x
|
26.5
x
|
FCF Yield
|
1.36%
|
-
|
1.68%
|
2.08%
|
3.77%
|
Price to Book
|
22.4
x
|
11.7
x
|
8.62
x
|
4.88
x
|
3.51
x
|
Nbr of stocks (in thousands)
|
6,941
|
7,144
|
7,099
|
-
|
-
|
Reference price
2 |
3,435
|
2,426
|
1,740
|
1,740
|
1,740
|
Announcement Date
|
12/05/22
|
12/05/23
|
14/05/24
|
-
|
-
|
Fiscal Period: March |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
5,782
|
6,657
|
8,284
|
9,950
|
11,700
|
EBITDA
1 |
-
|
598
|
621.5
|
856
|
1,181
|
1,541
|
EBIT
1 |
-
|
519
|
530
|
707
|
1,050
|
1,400
|
Operating Margin
|
-
|
8.98%
|
7.96%
|
8.53%
|
10.55%
|
11.97%
|
Earnings before Tax (EBT)
1 |
-
|
487
|
534
|
820
|
1,040
|
1,390
|
Net income
1 |
97.14
|
328
|
382
|
441
|
735
|
980
|
Net margin
|
-
|
5.67%
|
5.74%
|
5.32%
|
7.39%
|
8.38%
|
EPS
2 |
14.50
|
47.90
|
53.92
|
62.06
|
104.6
|
139.5
|
Free Cash Flow
1 |
-
|
319
|
-
|
214
|
260
|
453
|
FCF margin
|
-
|
5.52%
|
-
|
2.57%
|
2.61%
|
3.87%
|
FCF Conversion (EBITDA)
|
-
|
53.35%
|
-
|
25%
|
22.02%
|
29.4%
|
FCF Conversion (Net income)
|
-
|
97.26%
|
-
|
36.46%
|
35.37%
|
46.22%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/11/21
|
12/05/22
|
12/05/23
|
14/05/24
|
-
|
-
|
Fiscal Period: March |
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
2,767
|
1,507
|
1,508
|
1,534
|
1,634
|
3,168
|
1,753
|
1,736
|
1,795
|
2,104
|
3,899
|
2,197
|
2,188
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
226
|
134
|
159
|
128
|
-
|
254
|
144
|
132
|
55
|
146
|
201
|
264
|
242
|
Operating Margin
|
8.17%
|
8.89%
|
10.54%
|
8.34%
|
-
|
8.02%
|
8.21%
|
7.6%
|
3.06%
|
6.94%
|
5.16%
|
12.02%
|
11.06%
|
Earnings before Tax (EBT)
|
220
|
-
|
-
|
137
|
-
|
263
|
120
|
-
|
55
|
-
|
199
|
267
|
-
|
Net income
1 |
145
|
86
|
97
|
91
|
-
|
178
|
82
|
122
|
36
|
98
|
134
|
182
|
125
|
Net margin
|
5.24%
|
5.71%
|
6.43%
|
5.93%
|
-
|
5.62%
|
4.68%
|
7.03%
|
2.01%
|
4.66%
|
3.44%
|
8.28%
|
5.71%
|
EPS
|
21.32
|
-
|
-
|
13.08
|
-
|
25.33
|
11.38
|
-
|
5.110
|
-
|
18.82
|
25.71
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
15/11/21
|
10/02/22
|
12/05/22
|
10/08/22
|
10/11/22
|
10/11/22
|
10/02/23
|
12/05/23
|
10/08/23
|
13/11/23
|
13/11/23
|
13/02/24
|
14/05/24
|
Fiscal Period: March |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
386
|
126
|
-
|
Net Cash position
1 |
-
|
389
|
317
|
-
|
-
|
327
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
0.4509
x
|
0.1067
x
|
-
|
Free Cash Flow
1 |
-
|
319
|
-
|
214
|
260
|
453
|
ROE (net income / shareholders' equity)
|
-
|
39.1%
|
30%
|
36.1%
|
34.4%
|
32.7%
|
ROA (Net income/ Total Assets)
|
-
|
22.3%
|
20.5%
|
19.5%
|
24.7%
|
27%
|
Assets
1 |
-
|
1,473
|
1,867
|
2,259
|
2,976
|
3,630
|
Book Value Per Share
2 |
-
|
153.0
|
208.0
|
231.0
|
357.0
|
496.0
|
Cash Flow per Share
|
-
|
57.80
|
65.10
|
-
|
-
|
-
|
Capex
1 |
-
|
101
|
214
|
350
|
300
|
300
|
Capex / Sales
|
-
|
1.75%
|
3.21%
|
4.21%
|
3.02%
|
2.56%
|
Announcement Date
|
15/11/21
|
12/05/22
|
12/05/23
|
14/05/24
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -11.95% | 78.97M | | -29.72% | 15.83B | | -22.89% | 12.31B | | -24.53% | 6.59B | | +15.23% | 6.45B | | -12.43% | 5.94B | | +0.29% | 4.66B | | +62.00% | 4.59B | | -5.94% | 3.96B | | -9.36% | 3.55B |
Other Drug Retailers
|